Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

Among patients with type 2 diabetes, no differences were found with biguanides vs DPP-4 inhibitors in major cardiac or cerebrovascular events, diabetic complications, or death. Biguanides vs ...

GLP-1 receptor agonist use was associated with a reduced risk of progressing to cirrhosis and related complications in ...

Su Yu-cheng (right)shares his experience of serving as the flag bearer for the Chinese Kendo team during the opening ceremony ...

The man who defecated on the Marina Bay Sands floor last year was arrested on June 4 after he tried to enter the building.

It seems like a day doesn’t go by without another positive finding for the glucagon-like peptide 1 (GLP-1) receptoragonist ...

In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor ...

A 37-year-old construction worker from India was fined SGD400 on Thursday for defecating on Oct 30 last year at the entrance ...

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...

SINGAPORE — A 37-year-old construction worker was fined S$400 on Thursday (Sept 19) for defecating at the entrance of The ...

“(I am) thankful prosecution is still being considered by DPP, but have a number of concerns including the ... Since then he ...